Cannabis-based epilepsy treatment Epidiolex will cost $32,500 annually
The expensive price tag means that the parents of children with Lennox syndrome and Dravet syndrome may search for cheaper CBD-based treatments elsewhere
Bethan Rose Jenkins, Cannabis News Writer/Editorial
• August 29, 2018
CEO of GW Pharma talks about Epidiolex getting FDA approval
The DEA must accurately categorize CBD within 90 days of the approval
Bethan Rose Jenkins, Cannabis News Writer/Editorial
• July 2, 2018
Rescheduling cannabis in the States: Could the decision backfire?
Rescheduling the plant means that, although it would still be a regulated drug, cannabis would become legal for medicinal use
Bethan Rose Jenkins, Cannabis News Writer/Editorial
• June 17, 2018
Will Epidiolex be the first cannabis-based drug to be approved as an epilepsy treatment?
Bethan Rose Jenkins, Cannabis News Writer/Editorial
• May 3, 2018
FDA gives positive review for GW Pharmaceuticals’ cannabis-based medicine Epidiolex
Bethan Rose Jenkins, Cannabis News Writer/Editorial
• April 19, 2018
WHO declares CBD as safe for human consumption
February 22, 2018
New study: nearly 70 percent of CBD extracts labeled incorrectly
Sara Tiradossi
• November 10, 2017
A new bill could completely change cannabis research
September 20, 2017
Sessions further impedes cannabis research
Logan Lowrey-Rasmussen
• August 21, 2017
Load More Stories